AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019

BACKGROUND: This phase 3 trial assessed AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis against symptomatic coronavirus disease 2019 (COVID-19). METHODS: Adults without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 vaccination were enrolled w...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Myron J, Ustianowski, Andrew, Thomas, Steven, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Houlihan, Catherine F, Menendez-Perez, Ibrahim, Pollett, Simon, Arends, Rosalinda H, Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J, Koh, Gavin C K W, Ivanov, Stefan, Near, Karen A, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069855/
https://www.ncbi.nlm.nih.gov/pubmed/36411267
http://dx.doi.org/10.1093/cid/ciac899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069855/
https://www.ncbi.nlm.nih.gov/pubmed/36411267
http://dx.doi.org/10.1093/cid/ciac899

Ejemplares similares